Danaher Co. to Post Q2 2024 Earnings of $1.56 Per Share, William Blair Forecasts (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Analysts at William Blair decreased their Q2 2024 earnings per share estimates for Danaher in a report issued on Wednesday, April 24th. William Blair analyst M. Larew now forecasts that the conglomerate will earn $1.56 per share for the quarter, down from their previous forecast of $1.61. The consensus estimate for Danaher’s current full-year earnings is $7.62 per share. William Blair also issued estimates for Danaher’s Q3 2024 earnings at $1.73 EPS, Q4 2024 earnings at $2.45 EPS, Q1 2025 earnings at $2.29 EPS, Q2 2025 earnings at $1.86 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.77 EPS and FY2025 earnings at $8.90 EPS.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the prior year, the firm posted $2.36 earnings per share. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year.

Other equities analysts have also issued research reports about the company. Bank of America increased their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. Raymond James increased their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Citigroup increased their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays increased their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $270.00.

Danaher Trading Down 1.8 %

NYSE:DHR opened at $245.82 on Thursday. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00. The business’s 50-day moving average price is $248.94 and its two-hundred day moving average price is $230.88. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $182.04 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 4.24 and a beta of 0.83.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders sold a total of 84,132 shares of company stock worth $21,022,795 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Danaher

Hedge funds have recently made changes to their positions in the business. Banco Santander S.A. bought a new position in Danaher during the third quarter worth about $683,000. First Citizens Bank & Trust Co. increased its holdings in shares of Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after buying an additional 142 shares during the period. Finally, Keybank National Association OH grew its position in Danaher by 0.5% during the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after buying an additional 2,567 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.